Introduction {#S0001}
============

Multidrug-resistant (MDR) gram-negative bacilli, mainly *Pseudomonas aeruginosa* (*P. aeruginosa*) and *Acinetobacter baumannii* (*A. baumannii*), are major nosocomial pathogens worldwide \[[@CIT0001]--[@CIT0003]\]. The emergence of infections caused by multidrug-resistant Gram-negative bacteria poses a great challenge for infection control \[[@CIT0004]--[@CIT0006]\].

Colistin, also called polymyxin E, is a polypeptide antibiotic. Colistin is commercially available as colistin sulfate (for oral and topical use) and colistimethate sodium (for parenteral use, intravenously and intramuscularly) \[[@CIT0007]\]. Also, both forms can be administered by inhalation \[[@CIT0008]\]. Although colistin showed excellent activities against many species of gram-negative bacteria *in vitro* \[[@CIT0009], [@CIT0010]\], use of colistin has been limited due to limited clinical efficacy and significant nephrotoxicity and neurotoxicity. During the last 2 decades, colistin was mainly restricted to treat acute exacerbations of lung infections in patients with cystic fibrosis \[[@CIT0005], [@CIT0011], [@CIT0012]\]. However, the increasing frequency of pulmonary infections and lack of new agents effective against the resistant strains have led to the reconsideration of colistin \[[@CIT0008]\]. Some reports have demonstrated that modified dosage of colistin could be used as a therapeutic intervention for patients with pulmonary infections due to MDR *P. aeruginosa* and *A. baumannii* \[[@CIT0007], [@CIT0008], [@CIT0013], [@CIT0014]\].

Nevertheless, whether colistin in the treatment of Gram-negative bacteria infection is superior to other antibiotics is controversial \[[@CIT0015]--[@CIT0018]\]. Meta-analysis is a statistical procedure for combining the results of several studies to produce a single estimate of the major effect with enhanced precision \[[@CIT0019]--[@CIT0021]\], and it is considered as a powerful tool for summarizing inconsistent results from different studies. Hence, the aim of the present meta-analysis was to systematically evaluate the efficacy and safety of colistin in the treatment of pulmonary infection caused by *P. aeruginosa* or *A. baumannii*.

Material and methods {#S0002}
====================

Literature search {#S20003}
-----------------

Electronic databases including PubMed, MEDLINE, EMBASE, Springer, Elsevier Science Direct, Cochrane Library and Google Scholar were searched for all publications on colistin treatment in patients with pulmonary infection caused by *P. aeruginosa* or *A. baumannii* up to December 2012 without language restrictions. The main search terms were "colistin" OR "polymyxin" OR "polymyxin E" AND "pulmonary infection" OR "lung infection" AND "Pseudomonas aeruginosa" OR "Acinetobacter baumannii" OR "Gram-negative bacilli" AND "study" OR "trial". Meanwhile, references from retrieved papers were checked for any additional studies. We only recruited data from the full published paper, not any meeting or conference abstract. Two investigators (HZ and QZ) independently searched the electronic databases.

Inclusion and exclusion criteria {#S20004}
--------------------------------

Studies were included in the meta-analysis if they met the following criteria: 1) The investigations concerned patients with bronchiectasis (prospective studies, retrospective studies or cross-sectional studies, etc.); 2) The objects were the pulmonary infected patients (range of age was not limited); 3) The method of treatment was colistin against other relevant antibiotic treatment (ways of application of the drugs were not limited); 4) The effect size was the odds ratio. Sample size was not limited; 5) Studies were published in the English language. Studies were excluded if one of the following existed: 1) reduplicated studies or records; 2) review of literature; 3) no control design.

Quality assessment and data extraction {#S20005}
--------------------------------------

Quality was assessed using the factors mainly including the methods of studies, sample size, and recruitment of respondents. Initial screening was done by reading the document title and abstract. Secondary screening was conducted by reading the full text of papers. Finally, studies were included according to the inclusion and exclusion criteria. Data items included study details (such as the first author\'s name, research year of study, year of publication, location of participants, and method of studies), characteristics of participants (such as age and sample size), and Acute Physiological and Chronic Health Evaluation II (APACHE II) score. We contacted authors of the included studies to obtain further information about data items. We used standardized data extraction forms to record the first author\'s name, time of study, time of publication, country, geographic location, sample size, age, study method and events of the colistin group versus the control group. Quality assessment and data extraction were independently conducted by two investigators. Disagreements were resolved by discussion to come to an agreement.

Statistical analysis {#S20006}
--------------------

Our primary analysis was focused on a comparison of the odds ratios (*ORs*) in the colistin treated versus non-colistin treated patients with pulmonary infection caused by *P. aeruginosa* or *A. baumannii* (colistin group vs. control group). Then, stratified analysis by sample size, research year, participants' geographic location and study method was also conducted.

The meta-analysis was performed using fixed or random effect models. The point estimates of the odds ratio (*OR*) and its 95% confidence interval (95% CI) were estimated for each study. We assessed the within- and between-study variation or heterogeneity by testing Cochran\'s Q-statistic and *I*^2^-statistic \[[@CIT0022], [@CIT0023]\]. Values of *p* \< 0.10 or *I* ^2^ value \> 50% was considered to be heterogeneous. When heterogeneity was detected across studies, the random effect model was used for meta-analysis as well as to take into account the possibility of heterogeneity between studies. Otherwise, the fixed effect model was used. The fixed effect model assumes that all of the studies are estimating the same underlying effect and considers only within-study variation. The overall or pooled estimate of *ORs* was obtained using the Mantel-Haenszel method in the fixed effect model \[[@CIT0024]\] and using the DerSimonian and Laid method in the random effect model \[[@CIT0025]\]. Pooled *ORs* in the meta-analysis were calculated by weighting individual *ORs* by the inverse of their variance. The significance of the pooled *ORs* was determined by the *Z*-test.

A funnel plot was used to detect publication bias. An asymmetric plot infers a possible publication bias. The asymmetry of the funnel plot was further assessed using Egger\'s linear regression test \[[@CIT0026]\], which measures funnel plot asymmetry on the natural logarithm scale of the effect size. Values of *p* \< 0.05 was considered as indicating statistically significant publication bias.

In order to test the reliability of the results, we also performed a sensitivity analysis after removal of the study with biggest or smallest sample size to repeat the meta-analysis.

Analyses were performed using the software Review Manager 5.1 (Cochrane Collaboration, <http://ims.cochrane.org/revman>) and the STATA software package v.11.0 (Stata Corporation, College Station, TX, USA).

Results {#S0007}
=======

Characteristics of eligible studies {#S20008}
-----------------------------------

There were 4052 papers potentially relevant to the search terms (PubMed: 1206; MEDLINE: 783; Springer: 653; Elsevier Science Direct: 892; Cochrane Library: 55; Google Scholar: 463). The study selection process is shown in [Figure 1](#F0001){ref-type="fig"}. There were 365 potentially relevant studies after duplicates were removed. After reviewing the title and abstract, 326 of these articles were excluded (65 were review articles; 168 did not concern pulmonary infection; 93 did not report colistin data). After reviewing the full publication, 30 articles were excluded (18 for only reporting colistin data but not for comparison; 12 due to unavailable data).

![Flow diagram for selection of studies and specific reasons for exclusion from the meta-analysis](AMS-11-24346-g001){#F0001}

Finally, 9 studies \[[@CIT0001], [@CIT0009], [@CIT0016], [@CIT0027]--[@CIT0032]\] were included in this meta-analysis. The characteristics of the included studies are summarized in [Table I](#T0001){ref-type="table"}. The included studies were published between 2003 and 2012. Of the 9 included studies, 4 were conducted in Europe, 3 in America, 1 in Asia and 1 in Africa. A total of 940 patients with pulmonary infection caused by *P. aeruginosa* or *A. baumannii* were considered in this meta-analysis. Among them, 411 were treated with colistin (colistin group) and 529 were treated with other antibiotics such as ampicillin, sulbactam, cefepime, meropenem piperacillin or tazobactam (control group). The patients' age was between 3 and 103 years old. Sample size varied between 13 and 130. These included studies were cohort studies or case-control studies. The mean value of the APACHE II score was between 14.0 and 22.3.

###### 

Characteristics of studies included in the meta-analysis

  Study                       Publication year   Research year   Country                                           Ethnicity    Study method         Group            Sample size   Age (mean ± SD or min-max) \[years\]   Drug and dose                       APACHE II score (mean ± SD)
  --------------------------- ------------------ --------------- ------------------------------------------------- ------------ -------------------- ---------------- ------------- -------------------------------------- ----------------------------------- -----------------------------
  Betrosian *et al*.          2008               NA              Greece                                            European     Cohort study         Colistin group   15            67 ±9                                  Colistin (3 MU every 8 h)           14 ±2
  Control group               13                 72 ±5           Ampicillin/sulbactam (9 g every 8 h)              14 ±5                                                                                                                                       
  Durakovic *et al*.          2011               2002--2006      Croatia                                           European     Case-control study   Colistin group   26            35 (17--60)                            Colistin (3 MU every 8 h)           NA
  Control group               26                 37 (18--63)     Cefepime, meropenem, or piperacillin/tazobactam   NA                                                                                                                                          
  Garnacho-Montero *et al.*   2003               1997--2001      Spain                                             European     Cohort study         Colistin group   21            56.9 ±13.1                             Colistin (2.0--5.0 mg/kg per day)   19.6 ±7.2
  Control group               14                 64.5 ±11.0      Imipenem-cilastatin (2--3 g per day)              20.5 ±7.0                                                                                                                                   
  Hachem *et al*.             2007               2001--2004      United States                                     America      Case-control study   Colistin group   31            52 (10--72)                            Colistin (5.0 mg/kg per day)        17 (11--27)
  Control group               64                 62 (3--82)      A β-lactam antibiotic or a quinolone              16 (7--32)                                                                                                                                  
  Kallel *et al.*             2007               2003--2005      Tunisia                                           Africa       Case-control study   Colistin group   60            43.4 ±18.8                             Colistin (6 MU per day)             NA
  Control group               60                 41.4 ±16.7      Imipenem (2 g per day)                            NA                                                                                                                                          
  Koomanachai *et al*.        2007               2005--2006      Thailand                                          Asian        Cohort study         Colistin group   78            63.5 (18--103)                         Colistin (5.0 mg/kg per day)        21.9
  Control group               15                 58.9 (27--90)   Other antibiotics                                 22.3                                                                                                                                        
  Oliveira *et al.*           2008               1996--2004      Brazil                                            America      Case-control study   Colistin group   82            63 (8--87)                             Colistin (5.1 MU per day)           15 (3--39)
  Control group               85                 54 (7--89)      Ampicillin/sulbactam (9 g per day)                16 (1--50)                                                                                                                                  
  Reina *et al*.              2005               2000--2004      Argentina                                         America      Cohort study         Colistin group   55            40 ±16                                 Colistin (5.0 mg/kg per day)        21 ±7
  Control group               130                41 ±16          Carbapenems, sulbactam, tazobactam, etc.          20 ±7                                                                                                                                       
  Qin *et al*.                2012               2006--2010      France                                            European     Cohort study         Colistin group   43            58                                     Colistin (5 MU every 8 h)           NA
  Control group               122                59              Relevant intravenous antibiotics                  NA                                                                                                                                          

NA -- not available, MU -- million units.

Meta-analysis of efficacy of colistin versus other antibiotics {#S20009}
==============================================================

Overall meta-analysis as well as subgroup meta-analyses by sample size, research year, participants' geographic location (ethnicity) and study method were conducted to compare the efficacy of colistin against other antibiotics in treatment of pulmonary infection caused by *P. aeruginosa* or *A. baumannii*.

As shown in [Table II](#T0002){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}, a total of 9 separate studies \[[@CIT0001], [@CIT0009], [@CIT0016], [@CIT0027]--[@CIT0032]\], consisting of 940 patients (411 in the colistin group and 529 in the control group) were included in this meta-analysis. There was significant heterogeneity across the studies (*Q* ^2^ = 29.9, *I* ^2^ = 73.2%, *p* \< 0.01). The overall meta-analysis indicated that the pooled *OR* was 1.24 (95% CI = 0.68--2.27, *p* \> 0.05) for patients in the colistin group versus patients in the control group. The funnel plot was not symmetrical obviously, indicating that publication bias may exist. However, the result of Egger\'s linear regression showed no publication bias in the studies included in this meta-analysis (*t* = 1.76, *p* \> 0.05).

![Forest plot of studies with efficacy of colistin group versus control group](AMS-11-24346-g002){#F0002}

###### 

Pooled odds ratio of efficacy for patients in colistin group versus control group in meta-analyses (subgroup-analysis)

  Subgroups               No. of studies   Random model         Test of heterogeneity   Egger\'s test for publication bias                                     
  ----------------------- ---------------- -------------------- ----------------------- ------------------------------------ ------- --------- ------ -------- ------
  Overall effects         9                1.24 (0.68, 2.27)    0.69                    0.49                                 29.9    \< 0.01   73.2   1.76     0.12
  Sample size \< 40       5                2.15 (0.92, 5.00)    1.77                    0.08                                 9.17    0.057     56.4   --1.07   0.78
  Sample size ≥ 40        4                0.75 (0.41, 1.38)    0.93                    0.35                                 8.66    0.03      65.3   15.02    0.08
  Research year \< 2005   4                0.83 (0.36, 1.91)    0.44                    0.66                                 11.89   \< 0.01   74.8   --0.27   0.88
  Research year ≥ 2005    2                3.28 (0.31, 34.37)   0.99                    0.32                                 10.17   \< 0.01   90.2   8.79     --
  European                4                1.13 (0.65, 1.94)    0.43                    0.67                                 0.71    0.87      0      0        0.99
  America                 3                0.80 (0.29, 2.22)    0.42                    0.67                                 11.63   0.03      82.8   14.57    0.19
  Cohort study            5                1.49 (0.63, 3.54)    0.90                    0.37                                 13.31   0.01      69.9   1.91     0.52
  Case-control study      4                1.03 (0.40, 2.63)    0.06                    0.95                                 14.58   \< 0.01   79.4   6.96     0.2

The results of the further subgroup meta-analyses are shown in [Table II](#T0002){ref-type="table"}. The pooled *OR* was 0.75 (95% CI = 0.41--1.38, *p* \> 0.05) when considering 4 studies in which the sample size was more than or equal to 40, and the pooled *OR* was 2.15 (95% CI = 0.92--5.00, *p* \> 0.05) when considering 5 studies in which the sample size was less than 40. The pooled *OR* was 3.28 (95% CI = 0.31--34.37, *p* \> 0.05) for studies published in or after 2005, and the pooled *OR* was 0.83 (95% CI = 0.36--1.91, *p* \> 0.05) for studies published before 2005. The pooled *OR* was 1.13 (95% CI = 0.65--1.94, *p* \> 0.05) for studies conducted in Europea and 0.80 (95% CI = 0.29--2.22, *p* \> 0.05) for studies conducted in America. The pooled *ORs* were 1.49 (95% CI = 0.63--3.54, *p* \> 0.05) and 1.03 (95% CI = 0.40--2.63, *p* \> 0.05) for 5 cohort studies and 4 case-control studies, respectively.

No significant difference in efficacy between the colistin group and the control group was detected using overall and subgroup meta-analyses (*p* \> 0.05).

Meta-analysis of mortality of colistin versus other antibiotics {#S20010}
---------------------------------------------------------------

As shown in [Figure 3](#F0003){ref-type="fig"}, a total of 7 separate studies \[[@CIT0001], [@CIT0009], [@CIT0016], [@CIT0027], [@CIT0029], [@CIT0031], [@CIT0032]\], consisting of 635 patients (296 in the colistin group and 339 in the control group) with pulmonary infection caused by *P. aeruginosa* or *A. baumannii* were included in this meta-analysis. Significant heterogeneity was detected between studies (*Q*^2^ = 12.0, *I*^2^ = 50.0%, *p* \< 0.1). The overall meta-analysis indicated that the pooled *OR* was 1.05 (95% CI = 0.58--1.89, *p* \> 0.05) for patients in the colistin group versus patients in the control group. No significant difference in mortality was observed between the colistin group and the control group (*p* \> 0.05). We also performed Egger\'s linear regression test. The result showed that there was no publication bias in the studies included in this meta-analysis (*t* = 1.54, *p* \> 0.05).

![Forest plot of studies with mortality of colistin group versus control group](AMS-11-24346-g003){#F0003}

Meta-analysis of renal damage of colistin versus other antibiotics {#S20011}
------------------------------------------------------------------

As shown in [Figure 4](#F0004){ref-type="fig"}, a total of 6 separate studies \[[@CIT0001], [@CIT0009], [@CIT0016], [@CIT0027], [@CIT0029], [@CIT0032]\], consisting of 470 patients (253 in the colistin group and 217 in the control group) with pulmonary infection caused by *P. aeruginosa* or *A. baumannii* were included in this meta-analysis. No heterogeneity between studies was detected (*Q* ^2^ = 8.22, *I*^2^ = 39.0%, *p* \> 0.1). The overall meta-analysis indicated that the pooled *OR* was 1.25 (95% CI = 0.78--2.00, *p* \> 0.05) for patients in the colistin group versus patients in the control group. There was no significant difference in renal damage between the colistin group and the control group. No publication bias was detected in the studies included in this meta-analysis using Egger\'s linear regression (*t* = 1.49, *p* \> 0.05).

![Forest plot of studies with renal damage of colistin group versus control group](AMS-11-24346-g004){#F0004}

Evaluation of sensitivity analysis {#S20012}
----------------------------------

We performed a sensitivity analysis by removing one study each time and rerunning the model for the remainder of the studies to determine the effect on each overall estimate. The results showed that none of the individual studies substantially influenced the pooled *ORs*, which implied that our results were statistically reliable.

Discussion {#S0013}
==========

In the present meta-analyses, we retrieved 9 studies focused on the efficacy and safety of colistin treatment in the patients with pulmonary infection caused by *P. aeruginosa* or *A. baumannii*. We found that no significant difference in efficacy, mortality and renal damage was detected between colistin and other effective antibiotics. The combined estimate of our analysis was strong across multiple sensitivity analyses and without significant publication bias.

Due to its unsatisfactory efficacy and significant nephrotoxicity and neurotoxicity, use of colistin was limited in clinical practice \[[@CIT0013], [@CIT0033]\]. However, colistin recently re-entered clinical use with the increasing emergence of MDR Gram-negative bacteria in hospitals \[[@CIT0007], [@CIT0008], [@CIT0015]\]. Thus, it is necessary to re-assess the efficacy and safety of colistin treatment. However, the results were inconsistent among previous studies due to small sample sizes or low statistical power. For example, Oliveira *et al*. reported that ampicillin/sulbactam appears to be a more efficacious therapy than colistin, while Betrosian *et al*. suggested that colistin and ampicillin/sulbactam were comparably safe and effective treatments. We combined 9 studies and found that compared to other effective agents, colistin showed no significant difference in efficacy when treating pulmonary infection caused by MDR *P. aeruginosa* or *A. baumannii*.

The degree of heterogeneity is one of the major concerns in meta-analysis for the validity of the meta-analysis \[[@CIT0034], [@CIT0035]\], as non-homogeneous data are liable to result in misleading results. Significant heterogeneity was detected when comparing the efficacy of colistin treatment. To investigate whether the sample size, research year, participants' geographic location (ethnicity) or study method influenced the result, we also conducted a subgroup meta-analysis. We found that the heterogeneity between studies was decreased after stratifying the samples according to their different subgroups. For American samples, significant heterogeneity was observed under the recessive model, while no statistically significant heterogeneity was observed under any model in European samples. The results indicated that ethnicity might play an important role in genetic heterogeneity of patients with pulmonary infection caused by *P. aeruginosa* or *A. baumannii*. The subgroup analysis of clinical response also showed that there was no significant difference between colistin and control groups, suggesting that colistin and other antibiotic therapies are equally efficacious. Asia and Africa as participants' geographic location were not included in the subgroup analyses, due to there being only one study in each region. In addition, dosage and ways of application of drugs were not investigated using the subgroup meta-analysis because these data cannot be extracted in all literatures.

Safety of colistin treatment was also compared with that of other antibiotic therapies using overall meta-analysis. We found that neither hospital mortality nor renal damage was affected by the treatment with colistin or other effective agents, suggesting that colistin also acts as a safe drug in the treatment of pulmonary infection. Actually, colistin is a concentration-dependent drug \[[@CIT0036], [@CIT0037]\]. In clinical practice, the dosage of colistin was adjusted according to the level of serum creatinine that represents renal function \[[@CIT0032]\]. Thus, no significant renal toxicity of colistin could be explained.

Publication bias is another important factor affecting the quality of meta-analysis. Meta-analyses are prone to publication bias, the problem of selective publication of studies with positive results \[[@CIT0038]\]. The result of Egger\'s test demonstrated that there was no publication bias in this study (all *p* values \> 0.05). Moreover, the result of sensitivity analysis by removing one study each time and rerunning the model to determine the effect on each overall estimate implied that our results were statistically reliable.

Some limitations of this study should be discussed. First of all, only published studies were included in the present meta-analysis. Thus, publication bias may have occurred, although the use of a statistical test did not show it. Secondly, significant between-study heterogeneity was detected in the current meta-analysis, and may be distorting the meta-analysis. However, it was not a major problem because we did subgroup analysis to reduce the heterogeneity. Meanwhile, different populations may contribute to the heterogeneity. These results should be interpreted with caution because the population from each country was not uniform. Finally, considering that recruited studies were non-RCT and the number of studies was small, more high-quality RCTs are needed to test and verify the results of this meta-analysis. Therefore, we minimized the likelihood of bias by developing a detailed protocol before initiating the study, performing a meticulous search for published studies and using explicit methods for study selection, data extraction and data analysis.

In conclusion, our findings suggest that colistin is a safe and effective drug and could be used as an alternative agent in patients with pulmonary infection caused by MDR *P. aeruginosa* or *A. baumannii*.

We would like to thank all respondents of the study and all the people who gave help for this study.

Conflict of interest {#S0014}
====================

The authors declare no conflict of interest.
